These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11903303)

  • 1. Mineralocorticoids and cardiac fibrosis: the decade in review.
    Funder J
    Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1002-6. PubMed ID: 11903303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoids, salt, hypertension: effects on the heart.
    Young MJ; Funder JW
    Steroids; 1996 Apr; 61(4):233-5. PubMed ID: 8733007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cardiac fibrosis by aldosterone.
    Lijnen P; Petrov V
    J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states.
    Young M; Head G; Funder J
    Am J Physiol; 1995 Oct; 269(4 Pt 1):E657-62. PubMed ID: 7485478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
    Takeda Y; Yoneda T; Demura M; Usukura M; Mabuchi H
    Circulation; 2002 Feb; 105(6):677-9. PubMed ID: 11839620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
    Pasquale PD; Stefano GD; Paterna S
    Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression.
    Martín-Fernández B; de las Heras N; Miana M; Ballesteros S; Delgado C; Song S; Hintze T; Cachofeiro V; Lahera V
    J Cardiovasc Pharmacol; 2011 Jan; 57(1):114-21. PubMed ID: 20980916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
    Martín-Fernández B; de las Heras N; Miana M; Ballesteros S; Valero-Muñoz M; Vassallo D; Davel AP; Rossoni LV; Cachofeiro V; Lahera V
    Exp Physiol; 2012 Jun; 97(6):710-8. PubMed ID: 22327331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.
    Kagiyama S; Matsumura K; Fukuhara M; Sakagami K; Fujii K; Iida M
    Hypertens Res; 2007 Oct; 30(10):979-89. PubMed ID: 18049031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis.
    Rickard AJ; Funder JW; Fuller PJ; Young MJ
    Endocrinology; 2006 Dec; 147(12):5901-6. PubMed ID: 16990342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid-induced sodium appetite and renal salt retention: evidence for common signaling and effector mechanisms.
    Fu Y; Vallon V
    Nephron Physiol; 2014; 128(1-2):8-16. PubMed ID: 25376899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
    Kagiyama S; Matsumura K; Goto K; Otsubo T; Iida M
    Regul Pept; 2010 Feb; 160(1-3):133-9. PubMed ID: 19969025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extra-adrenal mineralocorticoids and cardiovascular tissue.
    Slight SH; Joseph J; Ganjam VK; Weber KT
    J Mol Cell Cardiol; 1999 Jun; 31(6):1175-84. PubMed ID: 10371693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
    Young MJ
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):174-80. PubMed ID: 18277151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptors and hypertension.
    Funder JW
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):53-5. PubMed ID: 7626506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone, mineralocorticoid receptors and vascular inflammation.
    Funder JW
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?
    Rickard AJ; Funder JW; Morgan J; Fuller PJ; Young MJ
    Endocrinology; 2007 Oct; 148(10):4829-35. PubMed ID: 17640982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.